Saturday, May 23, 2020 2:53:21 PM
Completing new trials is not nearly as important as seeing what amounts to interim data that's positive. Why? Because if it's positive in certain additional cancers, Doctor's don't have to wait for FDA approval, once the drug is approved for one disease it can be used off label for others.
Some Doctors knowing it's history might do it immediately, especially if they have patients where nothing else is working, essentially it's like compassionate use, but not the company is paid for the drug. Anecdotal evidence will grow, and as it does, more Doctors will try it.
If you consider the above, and believe that at least some of the off label use will prove positive, how would you value the company. Perhaps even more importantly, when DCVax-Direct trials resume, I believe they'll be done with multiple cancers, again if interim peeks at that trial appear positive in a number of cancers, how does this add.
I believe that those who say this company could grow to a market cap going into triple digit billions are right, but only if further trials actually prove that many cancers benefit from the use of both drugs. It's not to say the vaccines by themselves are curative, but rather that patients benefit from their use. Perhaps in combinations with other therapies you achieve a cure, perhaps people just live substantially longer.
This Thanksgiving I'll be 7 years post diagnosis of leukemia, I'm currently 5 years post stem cell transplant. I wish I could say I was cured, but I remain on chemo as my Dr. still believes it's the best insurance against it reoccurring. If I dropped the chemo, the odds would still be about 70% on my side that it wouldn't come back, I certainly don't like the side effects, but I'd rather accept them then face what I'd have to if it did come back.
As I understand the side effects of our vaccine, they're tiny by comparison to what people experience with most other forms of treatment. Even if cures are unobtainable, if life extensions of years and good quality of life is the result for a fair percentage, and it proves to work for many cancers, I believe the earnings will certainly go into double, and perhaps even triple digit billions over time, you can pick the P/E you believe is reasonable to arrive at what the stock price could be at that time. Of course if the company is bought out, the price ends at the buyout price, but if it's partnered, even if the partner effectively has control, it's unlimited as to how high it may go. I like the partnership because with it, essentially immediately, the company would have the financial resources to initiate new trials, they wouldn't need to wait for earnings to do so, or greater dilution.
Gary
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM